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Abstract
Background: Traumatic brain injury (TBI) initiates a complex series of neurochemical and signaling changes that lead to
pathological events including neuronal hyperactivity, excessive glutamate release, inflammation, increased blood-brain
barrier (BBB) permeability and cerebral edema, altered gene expression, and neuronal dysfunction. It is believed that a drug
combination, or a single drug acting on multiple targets, may be an effective strategy to treat TBI. Valproate, a widely used
antiepileptic drug, has a number of targets including GABA transaminase, voltage-gated sodium channels, glycogen
synthase kinase (GSK)-3, and histone deacetylases (HDACs), and therefore may attenuate a number of TBI-associated
pathologies.
Methodology/Principal Findings: Using a rodent model of TBI, we tested if post-injury administration of valproate can
decrease BBB permeability, reduce neural damage and improve cognitive outcome. Dose-response studies revealed that
systemic administration of 400 mg/kg (i.p.), but not 15, 30, 60 or 100 mg/kg, increases histone H3 and H4 acetylation, and
reduces GSK-3 activity, in the hippocampus. Thirty min post-injury administration of 400 mg/kg valproate improved BBB
integrity as indicated by a reduction in Evans Blue dye extravasation. Consistent with its dose response to inhibit GSK-3 and
HDACs, valproate at 400 mg/kg, but not 100 mg/kg, reduced TBI-associated hippocampal dendritic damage, lessened
cortical contusion volume, and improved motor function and spatial memory. These behavioral improvements were not
observed when SAHA (suberoylanilide hydroxamic acid), a selective HDAC inhibitor, was administered.
Conclusion/Significance: Our findings indicate that valproate given soon after TBI can be neuroprotective. As clinically
proven interventions that can be used to minimize the damage following TBI are not currently available, the findings from
this report support the further testing of valproate as an acute therapeutic strategy.
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Introduction
The cognitive and behavioral dysfunctions associated with
traumatic brain injury (TBI) are thought to be due to both the
initial injury, and a series of progressive damages and secondary
pathologies [1]. These include altered homeostasis due to
disruption of the blood-brain barrier (BBB), excessive release of
excitatory neurotransmitters, axonal and dendritic disruptions,
neuroinflammation, post-traumatic seizures (PTS), and cell death
[2–5]. PTS are prominent secondary pathologies [6] that can
cause excessive release of excitatory neurotransmitters, alterations
in blood pressure, decreased oxygen delivery, elevations in
intracranial pressure, and an increase in neuronal death following
TBI. Based on the complexity of the responses of the brain to
trauma, a recent National Institutes of Health working group on
TBI recommended either combination therapies or the evaluation
of agents that act on multiple mechanisms be evaluated as
treatment options for TBI [7].
Valproate [2-propylpentanoic acid] (VPA) is one of the most
commonly prescribed antiepileptic medications that has been
shown to reduce the neuronal damage associated with epileptic
activity. For example, in a model of rodent status epilepticus, VPA
markedly decreased neuronal damage in the hippocampal
formation and improved neurological and memory functions [8].
Following TBI, VPA has been shown to be effective in treating
early-, but not late-onset PTS [9]. It is thought that the
antiepileptic activity of VPA results from a combination of its
influence on a number of targets in the central nervous system
including inhibition of GABA transamination, reduction of
NMDA-mediated neuronal excitation, inhibition of histone
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blockade of voltage-gated sodium and T-type calcium channels
[10]. As altered GABAergic and glutamatergic neurotransmission,
decreased histone acetylation, and calcium entry have all been
implicated in TBI pathology, we questioned if VPA can be used as
a treatment option following TBI.
In this report, we demonstrate that post-injury administration of
VPA causes a dose-dependent improvement in behavioral function
following experimental TBI. This improvement was associated
with a decrease in cortical contusion volume, improved BBB
integrity, and preservation of hippocampal dendritic integrity. Our
findings support the use of VPA as a treatment for TBI, and
suggest its use merits further clinical investigation.
Materials and Methods
Materials
Male Sprague-Dawley rats (275–300 g) were purchased from
Charles River Laboratories (Wilmington, MA). Sodium valproate
was purchased from Sigma Aldrich (St. Louis, MO). Antibodies to
acetylated histone H3, acetylated histone H4, and total histone H4
were obtained from Millipore (Billerica, MA). Phospho ß-catenin
(Ser
33/37), total ß-catenin, phospho-ERK1/2 (Thr
202/Tyr
204,
Thr
185/Tyr
187), total ERK1/2 and double-cortin antibodies were
purchased from Cell Signaling Technology (Danvers, MA). Anti-
MAP2 antibodies were obtained from Covance (Princeton, NJ)
and the CD68 antibody purchased from Serotec (Raleigh, NC).
Production of brain injury
All experimental procedures were approved by the Animal
Welfare Committee of the University of Texas Health Science
Center at Houston and were conducted in accordance with the
recommendations provided in the Guide for the Care and Use of
Laboratory Animals. Protocols were designed to minimize pain and
discomfort during the injury procedure and recovery period. An
electromagnet-driven controlled cortical impact (CCI) device was
used to cause brain injury as previously described [11–13]. Briefly,
animals were anesthetized using 5% isofluorane with a 1:1 O2/
N2O mixture, mounted on a stereotaxic frame, and a midline
incision made. For BBB, a unilateral 6-mm crainiectomy was
prepared midway between the bregma and lambda with the
medial edge of the craniectomy 1-mm lateral to the midline as
described by Meaney et al [14]. For behavior, bilateral
craniectomies were produced. Rats received a single impact
(2.7 mm deformation) on the right parietal lobe with an impact
velocity of 6 meters/sec. Core body temperature was maintained
at 37–38uC by use of a heating pad. The animals were given time
to recuperate in a warming chamber before being returned to their
home cages. Animals were weighed daily after the injury for the
first 3 days, then weekly thereafter.
Drug preparation and administration
Sodium valproate (VPA) was dissolved in sterile saline to a final
concentration of 60 mg/ml (for the 400 mg/kg dose) or 15 mg/ml
(for the #100 mg/kg doses). For testing the influence of VPA on
cognitive function, animals were injured then injected (i.p.) with
the designated amount of VPA or an equal volume of vehicle 30
minutes or 3 hours post-injury, and every 24 hours thereafter for
the first 5 days post-injury. For biochemical analysis, uninjured
rats were given a single i.p. injection of VPA (15, 30, 60, 100 or
400 mg/kg) or vehicle. For experiments involving suberoylanilide
hydroxamic acid (SAHA), the drug was prepared as a 100 mg/ml
stock in DMSO. Final DMSO concentration for injection was
40% in saline.
Sample Preparation
Hippocampal tissues were quickly removed while submerged in
ice cold artificial cerebral spinal fluid (10 mM HEPES pH 7.2,
1.3 mM NaH2PO4, 3 mM KCl, 124 mM NaCl, 10 mM dextrose,
26 mM NaHCO3 and 2 mM MgCl2) containing phosphatase
inhibitors (2 mM sodium fluoride, 2 mM sodium molybdate and
1 mM sodium orthovanadate). Tissues were homogenized (20
strokes) in 10 volumes of a buffer containing 10 mM Tris pH 7.4,
1 mM EGTA, 1 mM EDTA, 0.5 mM DTT, phosphatase
inhibitors (0.1 mM okadaic acid and 1 mM sodium orthovanadate)
and protease inhibitors (1 mM PMSF and 10 mg/ml leupeptin)
using a motorized teflon-glass homogenizer. The samples were
immediately aliquoted and frozen at 280uC.
Western Blotting
Hippocampal tissue extracts were sonicated (5 pulses of 1 second
each) using a Sonics Vibracell sonicator (Sonics & Materials, Inc.,
Newtown, CT) and a 0.4 mm diameter probe. The amount of
protein in each sample was determined by a Bradford assay using
bovine serum albumin (BSA) as the standard. Samples were
denatured at 95uC for three minutes in 16 NuPage SDS sample
buffer (Invitrogen, Carlsbad, Calif.). Equal amounts of protein were
loaded, electrophoresed, and transferred to Immobilon-P mem-
branes (Millipore, Billerica, MA) using the NOVEX X-Cell II
system (Invitrogen, Burlingame, CA) and the buffers provided by
the vendor. Membranes were blocked overnight in 5% BSA,
followed by a three-hour incubation in primary antibodies (0.5 mg/
ml) at room temperature. Membranes were then washed and
incubated at room temperature with alkaline phosphatase (AP)-
conjugated secondary antibodies for one hour as recommended by
the vendor (Vector Laboratories, Burlingame, CA). Immunoreac-
tivity was detected using a chemiluminescence system and
quantified using Image J (freely available through NIH).
Measurement of BBB permeability
BBB permeability was assessed by measuring the extravasation
of Evans blue (EB) dye as described previously [15,16]. 3% EB in
saline was injected slowly through the Jugular vein (4 ml/kg) and
allowed to circulate for 1.5 hr. Following the circulation time,
animals were transcardially perfused with 1X PBS followed by 4%
paraformaldehyde. The brains were removed, cerebral hemi-
spheres were separated and 2 mm-thick sections were prepared for
each hemisphere. The brain sections from each hemisphere were
incubated in 5 ml 55uC formamide for 24 hr. At the end of the
incubation, tissues were removed and the formamide solution was
centrifuged at 20,0006g for 20 min in an Eppendorf centrifuge.
The supernatant solution was collected and the optical density at
620 nm was measured to determine the relative amount of EB dye
in each sample.
Assessment of motor function
All behavioral tests were conducted by an experimenter blind to
the treatment groups. Two different motor skill tasks (beam
balance and paw placement) were used to determine animals’
motor performance following injury [17,18] on days 1–3 post-
injury. For beam balance, rats were pre-assessed by placing them
on a narrow wooden beam (1.5 cm wide) and measuring the
duration they remained on the beam for up to 60 seconds. Animals
were given repeated pre-injury training until capable of balancing
on the beam for the entire 60 sec period in 3 consecutive trials.
Following injury, animals were given three daily trials during
which the length of time spent on the beam was recorded. Paw
placement was evaluated by placing the animal on a wire grid
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out of a total of 50 steps. A foot fault was defined as when a front
paw misses and appears below the plane of the grid. Paw
placement was repeated three times to give an average daily score.
Assessment of cognitive function
Rats were tested for their cognitive performance using the stan-
dard hidden platform version of the Morris water maze [12,19–21].
All animals had recovered from the TBI-associated motor
dysfunction prior to performing the cognitive testing. Animals were
given 4 consecutive training trials per day for 7 days, with an inter-
trial interval (iti) of 4 min. If the animal failed to locate the platform
within 60 sec on any given trial, it was led there by the
experimenter. Twenty-four hours following the last day of training,
animals were tested in a probe trial to measure quadrant preference
and platform localization. Movement within the maze was
monitored using a video camera linked to tracking software
(Ethovision, Noldus Information Technology, Leesbury, VA, USA).
Contusion volume measurement
Following the completion of the behavioral studies, approxi-
mately 28 days following the injury, animals were deeply
anesthetized with sodium pentobarbital (100 mg/kg) and trans-
cardially perfused with phosphate buffered saline (PBS) followed
by 4% paraformaldehyde. Brains were removed, post-fixed
overnight in perfusant, then cryoprotected in a 30% sucrose
solution. Cortical tissue loss was estimated essentially as described
previously [22], by experimenters kept blind with respect to the
treatment groups. In brief, cryosections (40 mm thickness)
spanning the rostral-caudal extent of the injured cortex were
selected and stained with cresyl violet by an experimenter given
only the animal’s identifier code. Images of the resultant slides
were then used for tissue loss measurement by a second
experimenter. The area of cortical tissue loss for each section
was carefully outlined using Adobe Illustrator, with the area of the
resultant outlines quantified by Image J, from the National
Institutes of Health. Contusion volume was calculated using the
equation A1(0.5X1) + A2(0.5X1+0.5X2) + An21(0.5Xn21 +0.5Xn) +
An(0.5Xn) where A is the area (mm
2) of the contusion for each
slice, and X is the distance (mm) between two sequential slices.
Once the contusion volume had been calculated for each animal,
the blind code was broken and group differences assessed.
Immunohistochemistry
To examine the consequences of TBI on histone acetylation, rats
were injured or sham-operated as described in the Production of cortical
impact injury section. For post-TBI histological evaluation, tissue
sections generated for the evaluation of cortical contusion volume
were used for immunohistochemistry. Free-floating slices were
incubated overnight in primary antibody (0.5–1.0 mg/ml) in TBS
containing 2% BSA and 2.5% normal goat serum. Immunoreac-
tivity was detected using species-specific secondary antibodies
coupled to Alexafluors. Disruptions in microtubule immunoreactiv-
ity were quantified for size and luminosity using digital images of
MAP-2 immunoreactivity and Image J. Luminosity was calculated as
the average of three measurements within a 75675 mmb o x
randomly placed within the damaged area. Luminosity was
normalized within each section by comparing to the luminosity
values obtained from adjacent, undamaged areas. For quantification
of neurogenesis, the number of doublecortin-positive cells embedded
within the granule cell layer of the dentate gyrus were counted in
three sections spanning the dorsal hippocampus by an independent
observer. The length of the dentate gyrus was measured, and the
number of cells/mm calculated. As several studies have shown that
cortical impact injury gives rise to widespread cellular and
biochemical changes in both the injured and contralateral
hemispheres [14,23–25], comparisons were made between injured
animals and sham-operated controls.
Statistical Analysis
For evaluation of behavioral data, repeated measures analyses
of variance (two-way or one-way as appropriate) and t-tests were
utilized to determine statistical differences. A Holm-Sidak method
for multiple comparisons post-hoc test was used to determine data
points with significant differences. Dose response western data was
evaluated using a one-way ANOVA followed by a Dunnet’s post-
hoc test. Data were considered significant at p#0.05 and presented
as Mean 6 Standard Error of the Mean (S.E.M.).
Results
Systemic valproate administration increases
hippocampal histone acetylation
Valproate (VPA) has been previously demonstrated to be an
inhibitor of histone deacetylase (HDAC) [26,27], and as such
preserves the acetylation of histones H2A, H3 and H4 [28]. To
examine the dose-response relationship between systemic VPA
administration and histone acetylation in the brain, western blots
were performed using acetyl-H3 and acetyl-H4 histone antibodies.
Rats were i.p. injected with designated amounts of VPA, and then
killed 45 min later. Hippocampal protein extracts were prepared
for western blots. All western blots were performed using starting
material amounts within the linear range of detection. The
representative western blots (Figure 1A) and summary data
(Figure 1B) show that systemic VPA administration (n=3/dose)
significantly increases both histone H3 and H4 acetylation in the
hippocampus (acetyl-H3: one way ANOVA F(5,15)=2.95,
P=0.047; acetyl-H4: one way ANOVA F(5,15)=4.89, P=0.008).
These changes occurred in a dose-dependent manner with
400 mg/kg dose significantly increasing hippocampal histone
acetylation compared to vehicle-treated controls. No significant
changes were detected when the levels of total H3 and H4 were
evaluated (H3: one way ANOVA F(5,15)=1.81, P=0.172; H4: one
way ANOVA F(5,15)=0.48, P=0.783). When expressed as a ratio
of acetylated:total histone levels, it was confirmed that 400 mg/kg
VPA significantly increases the acetylation of both histone H3
(Kruskal-Wallis one-way ANOVA on Ranks P=0.009) and
histone H4 (one way ANOVA F(5,15)=3.65, P=0.023).
In addition to its inhibition of HDAC, VPA has been shown to
activate the glycogen synthase kinase-3 (GSK-3)/ß-catenin and
extracellular signal-regulated kinase (ERK) pathways [10]. ß-
catenin is normally phosphorylated by GSK-3 targeting it for
ubiquitin-mediated degradation. By inhibiting GSK-3, VPA
causes the accumulation of non-phosphorylated ß-catenin that
leads to enhanced gene expression via the TCF/LEF family of
transcription factors [29]. To examine this consequence of VPA
administration, western blots were performed using phospho- and
total ß-catenin antibodies. Figure 1C shows a representative
western blot of phospho-ß-catenin and ß-catenin immunoreactiv-
ity following designated amounts of VPA injections. Figure 1D
shows that, similar to histone acetylation, ß-catenin is activated in
a dose-dependent fashion following VPA administration (phospho-
ß-catenin: one way ANOVA F(5,15)=5.67, P=0.004) with a
significant decrease observed at the 400 mg/kg dose. When the
ratio of phospho:total ß-catenin was used for statistical analysis, the
400 mg/kg dose of VPA was again found to significantly reduce ß-
catenin phosphorylation (one way ANOVA F(5,15)=4.96,
p=0.007). In contrast, no significant change was observed in the
VPA and TBI Dysfunction
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total levels (one way ANOVA F(5,15)=0.48, p=0.783) of ERK as a
result of VPA treatment at the time point examined (Figures 1E
and 1F). No significant difference was detected when phospho-
ERK immunoreactivity was normalized with respect to total ERK
immunoreactivity (one way ANOVA F(5,15)=1.49, p=0.252).
Qualitatively similar results were obtained when the ERK1 (p44)
and ERK2 (p42) were independently quantified (data not shown).
Valproate reduces TBI-associated blood-brain barrier
permeability
One of the key pathological changes that occurs acutely following
braininjury is disruptionofthe blood-brainbarrier (BBB). Recently,
Alam and colleagues have reported that acute treatment of rats
following hemorrhagic shock with valproate normalizes serum
claudin-3 levels, suggesting improved barrier function [30]. To
investigate if post-injury administration of VPA can reduce TBI-
associated BBB permeability, rats were anesthetized and given a
unilateral crainiectomy followed by cortical impact injury (3.3 mm
deformation). Thirty min later, rats were randomly divided into
either 400 mg/kg VPA (i.p.) or vehicle (0.9% sodium chloride)
groups. Forty-eight hours after the injury, animals were infused with
Evans Blue dye and brains removed for evaluation of barrier
integrity as described previously [31,32]. Rats treated with VPA
(n=9) were found to have significantly reduced Evans Blue
extravasation in their ipsilateral hemisphere than their vehicle-
Figure 1. Valproate increases hippocampal histone acetylation, and inhibits GSK-3 activity, in a dose-dependent manner. A) Picture
of a representative immunoblot showing histone H3 (a-H3) and H4 (a-H4) acetylation following systemic administration of different doses of
valproate (VPA). B) Summary data for acetylated histone H3 and acetylated histone H4 following different doses of i.p. injected VPA. C) Picture of a
representative western blot showing phosphorylated ß-catenin (p-ß-cat), and total b-catenin (ß-cat), immunoreactivities following VPA
administration. D) Summary data showing that VPA decreases b-catenin phosphorylation in a dose dependent manner. E) Picture of a
representative western blot showing phosphorylated (p-ERK) and total ERK immunoreactivity following VPA administration. F) Summary data
showing that VPA did not have any significant influence on ERK phosphorylation. Data are presented as mean 6 SEM, *,P#0.05.
doi:10.1371/journal.pone.0011383.g001
VPA and TBI Dysfunction
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cle=0.29860.028; 400 mg/kg VPA=0.19660.039; p=0.039).
Minimal Evans Blue was found in the contralateral hemisphere,
which did not change as a result of treatment (O.D./gram tissue:
vehicle=0.02060.010; 400 mg/kg VPA: 0.01660.006; p=0.302).
Valproate improves motor function following TBI
The influence of post-injury VPA injection on vestibulomotor
and motor function was tested from days 1–3 post-TBI using the
beam balance and foot fault tasks, respectively. For these studies,
rats were given bilateral crainiectomies, then injured by a single
impact to the right parietal cortex. Thirty min after the injury, rats
were i.p. injected with either 100 mg/kg VPA (or vehicle) or
400 mg/kg VPA (or vehicle). Drug administration was continued
every 24 hr for the first 5 days of injury. Neither 100 mg/kg VPA
(n=10, repeated measures two-way ANOVA: F(1,18)=0.08,
p=0.783) nor 400 mg/kg VPA given 30 min post-TBI (n=8,
repeated measures two-way ANOVA: F(1,15)=2.91, p=0.109)
significantly improved beam balance performance compared to
simultaneously tested vehicle controls (n=10 and n=9, respec-
tively) (data not shown). Figure 2A shows that the number of
contralateral foot faults, on the other hand, was found to be
significantly improved as a result of 100 mg/kg VPA treatment
(group main effect by repeated measures two-way ANOVA:
F(1,18)=4.38, p=0.050). This beneficial effect on motor perfor-
mance was also observed in the 400 mg/kg VPA-treated animals
(interaction of group and trial by repeated measures two-way
ANOVA: F(2,28)=3.74, p=0.036) (Figure 2B). Ipsilateral foot
faults were not affected by either treatment dose (data not shown).
One of the common side effects of valproate administration is
weight gain [33]. As TBI is associated with acute weight loss, and
this weight loss occurs during the time frame of motor skill testing,
we questioned if the improved motor skill performance we
observed could be due to a reduction in post-trauma weight loss.
Figure 2C shows that, contrary to our expectations, post-injury
administration of 100 mg/kg VPA had no effect on weight loss
(group main effect by repeated measures two-way ANOVA:
F(1,18)=0.02, p=0.901). At the highest dose tested, 400 mg/kg
VPA, a significant worsening of post-injury weight loss was
observed (interaction of group and day by repeated measures two-
way ANOVA: F(5,75)=10.40, p,0.001; Figure 2D).
Intraperitoneal injection of 400 mg/kg, but not 100 mg/
kg, valproate improves spatial learning and memory
To test the effects of post-injury VPA administration on the
cognitive deficits observed following TBI, rats were trained in the
hidden platform version of the Morris water maze. Testing began
on day 14 post-injury, and consisted of 4 trials/day for a total of 7
days. All animals had recovered from the vestibulomotor and
motor deficits by the time water maze performance was tested.
Figure 3A shows that injured animals treated with 100 mg/kg
VPA did not have learning curves that were significantly different
from their vehicle-injected counterparts (repeated measures two-
way ANOVA: F(1,18)=0.92, p=0.350). When tested in a probe
Figure 2. Post-injury valproate administration improves motor skills, but exacerbates injury-associated weight loss. Injured rats
treated 30 min post-injury with either A) 100 mg/kg valproate (VPA) or B) 400 mg/kg VPA had improved motor function as indicated by reduced
numbers of contralateral foot faults compared to simultaneously tested vehicle-treated controls. C) Post-injury weight loss is not affected by 100 mg/
kg VPA. In contrast, D) 400 mg/kg exacerbated the degree and duration of weight loss after injury. Data are presented as the mean 6 SEM. N,
significant difference by repeated measures two-way ANOVA. *, P#0.05.
doi:10.1371/journal.pone.0011383.g002
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not demonstrate a preference for the quadrant in which the
platform was located (repeated measures one-way ANOVA:
F(3,27)=0.04, p=0.989) indicating a lack of memory for the
location of the platform (Figure 3B). Although the 100 mg/kg
VPA-treated animals displayed improved localization to the target
quadrant, their performance did not reach statistical significance
(repeated measures one-way ANOVA: F(3,27)=2.64, p=0.070).
Likewise, Figure 3C shows that the number of platform crossings
did not significantly differ between the two groups (Mann-Whitney
Rank Sum Test: p=0.585).
In contrast to that observed for the 100 mg/kg VPA-treated
animals, Figure 3D shows that administration of 400 mg/kg VPA
significantly improved the performance of injured animals in the
water maze (group main effect by repeated measures two-way
ANOVA: F(1,15)=15.03, p=0.001). Post-hoc analysis revealed
that this difference was primarily due to significantly reduced
latencies to the hidden platform during the last 3 days of training,
suggesting an improved memory for the platform location.
Consistent with this suggestion, animals treated with 400 mg/kg
VPA performed better in a probe trial given 24 hr following
training as indicated by a significant quadrant preference in the
VPA-treated animals (repeated measures one-way ANOVA:
F(3,21)=3.11, p=0.048; Figure 3E) that was not observed in
injured rats treated with vehicle (repeated measures one-way
ANOVA: F(3,24)=1.65, p=0.205). In addition, rats given
400 mg/kg VPA had a significant increase in the number of
platform crossings (Mann-Whitney Rank Sum Test: p=0.046;
Figure 3F). Swimming speed was not significantly different
between the 400 mg/kg VPA- and vehicle-treated animals
(vehicle: 26.2761.32 cm/sec; 400 mg/kg VPA: 25.061.69 cm/
sec; P=0.529).
Three hour delayed administration of valproate
improved motor, but not cognitive, function
To test if a 3 hr delay can be used for treatment initiation,
injured animals were injected with either 400 mg/kg VPA or
vehicle then tested in motor and cognitive tasks as described
above. Treatment was continued by daily injections for the
following 4 days. Figure 4A shows that when the treatment was
delayed by 3 hr, improved motor function was still observed, as
indicated by significantly fewer contralateral foot faults in the
VPA-treated animals (n=9) than the vehicle-treated controls
(n=11) (repeated measures two-way ANOVA: F(1,18)=4.47,
p=0.048). Exacerbated weight loss as a result of treatment also
persisted in these animals (F(1,18)=7.15, p=0.015; Figure 4B).
However, no benefit of delayed VPA treatment was observed in
water maze learning (repeated measures two-way ANOVA:
F(1,18)=0.37, p=0.549; Figure 4C), nor in measures of memory
such as number of platform crossings (# of crossings: vehi-
Figure 3. Post-injury administration of 400 mg/kg, but not 100 mg/kg, valproate improves behavioral performance in brain injured
rats. Injured rats treated with either valproate (VPA) or vehicle 30 min post-injury were tested in the standard hidden platform version of the Morris
water maze. A) No difference in water maze performance was detected between the vehicle- and 100 mg/kg VPA-treated injured rats. Similarly,
when tested in a probe trial given 24 hr after the completion of training, there was no significant B) quadrant preference, nor C) difference in
number of platform crossings as a result of 100 mg/kg VPA treatment. In contrast, rats treated with 400 mg/kg had D) significantly improved water
maze performance that was associated with E) a preference for the target quadrant (quadrant I) and F) significantly more platform crossings during a
probe trial given 24 hr after the completion of training. Data are presented as the mean 6 SEM. N, significant group difference by repeated
measures two-way ANOVA. *, p#0.05.
doi:10.1371/journal.pone.0011383.g003
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quadrant preference (repeated measures one-way ANOVA:
F(3,24)=1.63, p=0.208; Figure 4D) compared to controls.
HDAC inhibition is not sufficient to mimic the beneficial
effects of valproate.
Previous reports have indicated that many of the neuroprotec-
tive properties of VPA are linked to its HDAC inhibitory activity
[34–36]. To test if the behavioral improvements observed
following 400 mg/kg VPA administration can be mimicked by a
more selective HDAC inhibitor, the influence of suberoylanilide
hydroxamic acid (SAHA) on TBI-associated motor and cognitive
dysfunction was examined. SAHA is a potent inhibitor of class I
and class II HDACs that has been used by a number of
investigators to assess the role of HDAC activity in pathological
conditions [37–41]. In order to examine the effectiveness of SAHA
on hippocampal histone acetylation, 50 mg/kg SAHA was
injected i.p. and protein extracts prepared 3 hr (n=4) and 6 hr
(n=3) later. This dose of SAHA has been previously demonstrated
to significantly increase histone acetylation in the mouse brain
[39]. Vehicle-injected rats (n=4) were used as controls. Figure 5A
shows that 50 mg/ml SAHA significantly increased the acetylation
of both histone H3 (one-way ANOVA: F(2,8)=5.61, p=0.030;
acetylated:total ratio: F(2,8)=4.86, p=0.042) and histone H4
(one-way ANOVA: F(2,8)=20.24, p,0.001; acetylated:total
ratio: F(2,8)=7.70, p=0.014) in the hippocampus. In contrast,
no significant influence on ß-catenin phosphorylation was
observed at the time points examined (one-way ANOVA:
F(2,8)=0.48, p=0.635; phosphorylated:total ratio: F(2,8)=0.17,
p=0.848) (Figure 5B), indicating no effect of SAHA on GSK-3
activity.
To test the behavioral consequences of post-injury SAHA
administration, rats were i.p. injected with either 50 mg/kg SAHA
(n=11) or an equal volume of vehicle (n=11) 30 min after the
injury. As was done for VPA, drug administration was continued
every 24 hr for the first 5 days of injury. Figure 5C shows that
unlike VPA, SAHA did not improve motor function as indicated
by similar numbers of contralateral foot faults (repeated measures
two-way ANOVA: F(1,20)=0.03, p=0.874). No significant differ-
ence was detected in either beam balance (repeated measures two-
way ANOVA: F(1,20)=0.04, p=0.853) or ipsilateral foot faults
(repeated measures two-way ANOVA: F(1,20)=0.08, p=0.785)
(data not shown). SAHA administration did reduce post-injury
weight loss (interaction of group and day by repeated measures
two-way ANOVA: F(6,120)=5.08, p,0.001) (Figure 5D), an effect
opposite to that seen following VPA treatment. When these
animals were tested in the Morris water maze, no significant
influence of SAHA administration was observed in either learning
(repeated measures two-way ANOVA: F(1,20)=1.66, p=0.212;
Figure 5E) or measures of memory during a 24 hr probe trial
(latency to platform: Student’s t-test P=0.134; number of platform
crossings: Mann Whitney Rank sum test P=0.477).
Figure 4. Delayed valproate administration improves motor skills, but does not improve cognitive function. A) Injured rats treated
3 hr post-injury with 400 mg/kg valproate (VPA) had improved motor function as indicated by reduced numbers of contralateral foot faults
compared to simultaneously tested vehicle-treated controls. B) Post-injury weight loss was exacerbated by delayed administration of 400 mg/kg
VPA. C) No difference in water maze performance was detected between the vehicle- and delayed VPA-treated injured rats. D) When tested in a
probe trial given 24 hr after the completion of training, there was no significant quadrant preference as a result of delayed VPA treatment. Data are
presented as the mean 6 SEM. N, significant group difference by repeated measures two-way ANOVA. *, p#0.05.
doi:10.1371/journal.pone.0011383.g004
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cortical contusion volume
Following the completion of the behavioral studies, VPA- and
vehicle-injected animals were euthanized and brains removed for
determination of contusion volume. Figure 6A shows photo-
graphs of the brains of a representative vehicle- and 400 mg/kg
VPA-treated animal (30 min post-injury treatment initiation).
The pictures show that the animal treated with 400 mg/kg VPA
had contralateral cortical tissue loss that appears to be
dramatically smaller in size than that seen in the vehicle-treated
animal. Quantification of this tissue loss revealed that 400 mg/kg
VPA significantly reduced contralateral tissue loss compared to
animals receiving vehicle injections (Student’s t-test: p=0.014;
Figure 6B). When examined over the rostral-caudal extent of the
injury, it was found that 400 mg/kg VPA reduced the magnitude
of damage primarily anterior to the contralateral injury core
(two-way repeated measures ANOVA: F(1,18)=6.271, P=0.021;
Figure 6C). This protection on contralateral tissue loss was not
observed in the animals treated with 100 mg/kg VPA (Student’s
t-test: p=0.362), nor in the 400 mg/kg VPA-treated animals
whose treatment was delayed by 3 hr following injury
(Student’s t-test: p=0.963). Influences on ipsilateral tissue loss
were not observed at any of the doses or times of administration
tested.
Improved spatial learning and memory are associated
with preserved hippocampal MAP2 immunoreactivity
Valproate has been previously demonstrated to induce dendritic
growth of cultured cells [42,43] and TBI has been shown to cause
disruption of hippocampal dendrites [20,44]. As our Morris water
maze results indicate that treatment of injured animals with
400 mg/kg VPA starting 30 min post-injury significantly improves
hippocampal function, we questioned if this improvement was
associated with preserved hippocampal dendritic integrity. To test
this, immunohistochemistry was performed using the dendritic
marker microtubule-associated protein 2 (MAP2). The tissue
sections prepared following the completion of the behavioral
studies were used for these experiments. Figure 7A shows a
representative photomicrograph of a hippocampus from a vehicle-
treated, injured animal immunoreacted for MAP2. Areas of
reduced MAP2 immunoreactivity can be seen in both the stratum
radiatum and stratum molecular. In contrast to that seen in
vehicle-treated animals, these disruptions appeared to be reduced
in rats treated 30 min post-injury with 400 mg/kg VPA
(Figure 7B). When the location of disruptions were recorded, it
was found that while most vehicle-treated animals had discernable
damage adjacent to the CA1/CA2 (80% of all animals examined)
and dentate gyrus (DG; 60% of all animals examined) subfields,
these damages were observed less frequently in the 400 mg/kg
Figure 5. Post-injury administration of SAHA does not mimic the behavioral improvement seen following valproate. A) Picture of a
representative immunoblot and summary data showing increased histone H3 and H4 acetylation following systemic administration of 50 mg/kg
SAHA. B) Picture of a representative western blot and summary data showing that the phosphorylation of ß-catenin is not affected by SAHA
administration. C) Injured rats treated 30 min post-injury with 50 mg/kg SAHA did not have improved motor function, as indicated by numbers of
contralateral foot faults, compared to simultaneously tested vehicle-treated controls. D) Post-injury weight loss was reduced by 50 mg/kg SAHA.
E) Injured rats treated with either SAHA or vehicle 30 min post-injury were tested in the standard hidden platform version of the Morris water maze.
No difference in water maze performance was detected between the two groups.
doi:10.1371/journal.pone.0011383.g005
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order to quantify the area and degree of MAP2 disruption, high
magnification photomicrographs (representative image shown in
Figure 7D) were taken, and the size and relative fluorescent
intensity of the region of MAP2 loss measured as described
previously [20]. Figure 7E shows that the cumulative area of TBI-
associated hippocampal MAP2 disruption/section was significant-
ly reduced in VPA-treated rats compared to that measured in
vehicle-treated controls (Student’s t-test p=0.049). Furthermore,
areas that had disruption were found to have increased MAP2
immunoreactivity (Student’s t-test p=0.016; Figure 7F), suggesting
spared fibers.
In addition to influences on dendritic growth, chronic valproate
treatment has been shown to enhance neurogenesis within the
hippocampus [45] and has been demonstrated to reduce
monocyte/macrophage accumulation [46]. To test if the rate of
TBI-associated increased neurogenesis [47–49] was influenced by
our VPA treatment regimen, the number of doublecortin positive
cells was counted. Representative photomicrographs from a
vehicle- (Figure 7G) and a VPA- (Figure 7H) treated animal are
shown. No significant difference was detected between the two
groups (quantified as # of cells/mm dentate gyrus: vehicle=12.09
61.22; 400 mg/kg VPA=12.2860.95, P=0.899; Figure 7I).
Similarly, although a dramatic increase in CD68-immunopositive
monocytes/macrophages was observed in the corpus callosum as a
result of injury, this did not appear to be affected by VPA
treatment (Figure S1).
Discussion
Using a rodent model of TBI, we examined if post-injury VPA
administration is neuroprotective, and improves motor and
cognitive outcomes. Our preclinical findings show that post-injury
systemic administration of VPA: 1) reduced cortical contusion
volume, 2) improved blood-brain barrier integrity (BBB), 3)
reduced hippocampal MAP2 disruptions, and 4) improved motor
and cognitive function.
Valproate [2-propylpentanoic acid] (VPA) is a simple branched-
chain fatty acid with well established efficacy for seizures [50]. It is
also commonly prescribed for bipolar disorder, acute mania and
migraines [10]. The therapeutic concentration of valproate is 40–
100 mg/ml, and it has a serum half-life of 8–17 hours in adults.
This therapeutic concentration is achieved by a loading dose (as
low as 10 mg/kg) followed by maintenance doses (as high as
60 mg/kg). In rodents, an i.p. dose of 200 mg/kg gives rise to a
peak serum concentration of 400 mg/ml 15 minutes post injection
that rapidly decreases to about 40 mg/ml by 8 hr post-infusion [8].
In contrast, an injection of 400 mg/kg gives rise to a plasma
concentration of approximately 150 mg/ml at 8 hr. A number of
studies have utilized 300 mg/kg or 400 mg/kg and have observed
HDAC and/or GSK-3 inhibition in the brain and other organs
[8,51–53]. Consistent with these studies, we found that 400 mg/kg
VPA significantly increased histone acetylation, and reduced b-
catenin phosphorylation in hippocampal tissue extracts (Figure 1).
Using a dose of 400 mg/kg, we observed that VPA improved
motor function, and enhanced spatial learning and memory.
Although the VPA-treated animals displayed a quadrant prefer-
ence when assessed in a 24 hr probe trial, post-hoc analysis
revealed that this difference was due to a preference for the target
quadrant (I) relative to only the starting quadrant (III). This
implies that although the VPA-treated, injured animals have better
long-term memory for the platform position than do vehicle-
treated injured animals, the performance of neither group was to
the level typically observed for uninjured animals The improve-
ment in motor and cognitive performance seen after acute VPA
treatment suggests that this compound may reduce TBI-associated
neuronal degeneration. Previous studies have reported that
valproate can be neuroprotective, both for cells grown in culture
and as well as in a rodent models of status epilepticus and ischemic
stroke [42,43,52]. For example, Ren et al reported that treatment
of rats with 300 mg/kg valproate following middle cerebral artery
occlusion (MCAO) significantly reduced infarct size and improved
neurologic recovery [52]. Consistent with this, our measurement
of cortical contusion volume showed that injured animals treated
30 min following injury with 400 mg/kg VPA had significantly
reduced cortical tissue loss than their vehicle-treated counterparts.
In addition, we found that TBI-associated disruption of hippo-
campal MAP2 immunoreactivity, an indicator of dendritic
damage, was also reduced in VPA-treated animals. This is
consistent with previous reports that have indicated that treatment
of neurons with valproate induces neurite outgrowth [42].
However, it is not known if the reduction in MAP2 disruption
we observed represents a preservation of dendritic integrity, or is
the result of dendritic outgrowth. In addition to influences on
Figure 6. Post-injury administration of 400 mg/kg valproate reduces contusion volume. A) Representative photographs of the brains
from a vehicle- and a 400 mg/kg valproate (VPA)-treated animal. Animals were killed 4 weeks post-injury. B) Quantification of the volume of lost
cortical tissue revealed that 400 mg/kg VPA significantly reduced contralateral tissue loss. C) Rostral-caudal extent of the damage detected in the
contralateral cortex from vehicle- and 400 mg/kg VPA-treated animals. Data are presented as the mean 6 SEM. N, significant difference by repeated
measures two-way ANOVA. *, P#0.05.
doi:10.1371/journal.pone.0011383.g006
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hippocampal neurogenesis [45]. Although we anticipated seeing
an influence of VPA on the rate of hippocampal neurogenesis, our
analysis of doublecortin positive cells examined after the
completion of behavioral training did not reveal any significant
increase in cell numbers relative to that observed in vehicle-
treated, injured animals. It has been reported that doublecortin is
expressed during the late mitotic and early post-mitotic stages of
neurogenesis (1–3 weeks post proliferation) [54,55]. As the animals
used for this analysis were euthanized approximately 4 weeks after
injury, it is possible that the neurons generated during the time of
VPA administration (given during the first week of injury) had
become synaptically integrated and were no longer doublecortin
positive. Alternatively, as both cortical impact injury and
behavioral training have also been shown to increase the rate of
hippocampal neurogenesis [49,56], this may have made it difficult
to detect VPA-mediated increases.
At present, the mechanism(s) underlying the protective effects of
VPA are not clear. As decreased histone acetylation has been
observed following TBI [57] (Figure S2), VPA may offer
protection, in part, by increasing histone acetylation and
enhancing the expression of genes involved in neuronal plasticity
and survival. Consistent with this, Shein et al., have shown that
acute treatment of mice following TBI with the HDAC inhibitor
ITF2357 reduces contusion volume and improves motor function
[58]. Further, Lyeth and colleagues have shown that DMA-PB (a
novel HDAC inhibitor) attenuates the TBI-associated decrease in
histone acetylation and reduces microglia-mediated inflammation
[59]. However, post-injury treatment with SAHA did not improve
motor or cognitive function, suggesting that the HDAC-inhibiting
activity of VPA is not sufficient to improve behavioral outcome
following TBI. Consistent with the result obtained using SAHA,
we have recently reported that post-injury treatment with sodium
butyrate, a non-selective HDAC inhibitor, also failed to improve
cognitive function when administered acutely following TBI [60].
In addition to inhibition of HDACs, the mood-stabilizing
properties of valproate are thought to be due to its ability to
inhibit GSK-3 [61]. Although the role of GSK-3 in TBI pathology
Figure 7. Post-injury treatment with 400 mg/kg valproate offers neuroprotection after TBI. Representative photomicrographs showing
microtubule-associated protein 2 (MAP2, a dendritic marker) immunoreactivity in the ipsilateral hippocampi of injured animals treated with either A)
vehicle or B) 400 mg/kg valproate (VPA). Arrows indicate areas of dendritic damage. C) Illustrations showing the location of, and percentage of
animals with, reduced MAP-2 immunoreactivity. D) High magnification photomicrograph showing a representative area with disrupted MAP2
immunoreactivity. E) Summary data showing the average of the cumulative area of reduced MAP-2 immunoreactivity from the hippocampi of vehicle
and 400 mg/kg VPA-injected injured animals. F) Average fluorescent intensity of the areas with reduced MAP-2 immunoreactivity from the
hippocampi of vehicle- and 400 mg/kg VPA-treated animals. Fluorescent intensity of the damaged area was normalized within each section by
comparison to the fluorescent intensity of an adjacent, undamaged area. Representative photomicrographs showing doublecortin immunoreactivity
from a G) vehicle- and a H) 400 mg/kg VPA-treated animal. I) Summary data showing that treatment with 400 mg/kg VPA had no effect on the
number of doublecortin positive cells by 4 weeks post-injury. Data are presented as mean 6 SEM. *, P#0.05. DG: dentate gyrus, so: stratum oriens,
sr:stratum radiatum, sm: stratum molecular.
doi:10.1371/journal.pone.0011383.g007
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critical for the regulation of ß-catenin-mediated gene expression
and has been implicated in the mechanism of action of several
neuropsychiatric drugs [62,63]. Alam and colleagues have shown
that valproate treatment enhances survival following lethal
hemorrhagic shock with and without polytrauma (300 and
400 mg/kg, respectively), and that this protection is associated
with nuclear translocation of ß-catenin and increased expression of
bcl-2 [51,64]. Recent studies have shown that valproate can also
elicit neuronal growth via activation of ERK [42]. We have
previously shown that the activation of ERK following TBI is
neuroprotective, and its inhibition exacerbates TBI-associated
motor and cognitive deficits [20]. Although our western blots did
not reveal any significant increase in ERK phosphorylation in
response to VPA injection, its activation at an earlier/later time
point than that examined here (45 min post-injection) cannot be
ruled out. Lastly, while not specifically examined in the current
study, valproate has also been shown to enhance GABAergic
neurotransmission. Previous studies have shown that administra-
tion of a GABA agonist acutely following injury can be used to
reduce hyperactivity and improve neurological outcome [65–67].
It is therefore plausible that one or a combination of these
mechanisms may underlie the beneficial influences of VPA we
observed.
At the doses and dosing regimens employed, no adverse
influences of VPA were observed except for an exacerbation of
post-injury weight loss at the 400 mg/kg dose. TBI is known to
cause an acute loss in body weight that is most likely due to reduced
food consumption during the acute phase of injury [68]. Evaluation
of body weight revealed that rats treated with 400 mg/kg VPA took
approximately twice as long to return to their pre-injury weights. It
has been reported that caloric restriction can be used to enhance
neuronal plasticity, increase resistance to oxidative stress, to reduce
insulin sensitivity and excitotoxicity [69,70]. Consistent with these
benefits, food restriction has been shown to be associated with a
recovery of spatial memory following global ischemia [71].
Although we cannot rule out any contribution that the enhanced
weight loss had on the cognitive improvements we observed, our
time window studies suggest that this was unlikely to be a
determining factor. This conclusion is based on our observation
that while both 30 min and 3 hr post-injury groups had enhanced
weight loss and motor skill improvement as a result of daily
400 mg/kg VPA injection, only the 30 min post-injury animals
displayed improved spatial learning and memory.
TBI patients often have trauma to other organs, resulting in
blood loss and hemorrhagic shock. Recently, Alam and colleagues
have shown that acute valproate can be used to reduce the
lethality of hemorrhagic shock in both rodent and swine models
[51,64]. These findings, along with our findings on the beneficial
effects of VPA treatment on BBB function, cognitive improvement
and neuronal protection, suggest that this drug may have benefit
in the treatment of TBI and TBI with polytrauma. One potential
limitation of valproate therapy to improve cognitive function is
that it appears to only be effective when given less than 3 hr post-
injury. Further experiments will be required to establish the exact
time window, the best routes of administration, and if this
improvement can be observed following different injury magni-
tudes [72].
Supporting Information
Figure S1 Valproate does not appear to reduce infiltration of
inflammatory cells. Valproate (VPA) has been demonstrated to
reduce monocyte/macrophage accumulation following experi-
mental autoimmune neuritis [46]. As increased monocyte
infiltration has been observed following TBI, we investigated if
400 mg/kg VPA can reduce the number of these cells.
Representative photomicrographs showing CD68 (a marker for
circulating monocytes/macrophages) immunoreactivity in the
ipsilateral hippocampi of sham, injured animals treated with
vehicle, and injured animals treated with 400 mg/kg valproate
(VPA). Dotted lines indicate the position of the hippocampal
neuronal layers. Although dramatic infiltration of CD68-positive
monocytes/macrophages can be observed in the corpus callosum
(cc) following injury, no overt influence of VPA was observed. DG:
dentate gyrus.
Found at: doi:10.1371/journal.pone.0011383.s001 (7.29 MB TIF)
Figure S2 TBI decreases histone acetylation in the hippocam-
pus. Jenkins and colleagues have recently demonstrated that
controlled cortical impact injury causes a decrease in hippocampal
histone acetylation in juvenile rats that is localized to the CA3
subfield [57]. To determine the influence of cortical impact injury
on histone acetylation in adult rats, hippocampal tissue samples
were prepared at various time points following injury and
subjected to western blot analysis using antibodies that specifically
detect either acetylated H3 or acetylated H4 histones. A)
Representative western blot showing histone H3 and H4
acetylation in hippocampal protein extracts at different time
points after TBI (n=4/time point). Summary results of the
changes in the acetylation for B) histone H3 (one-way ANOVA
F(4,15)=0.029, P=0.998) and C) histone H4 (one-way ANOVA
F(4,15)=0.350, P=0.840) after injury. In order to examine if
histone acetylation changed in a localized manner, immunohisto-
chemistry was performed on brain sections taken from sham-
operated and 24 hr post-injury animals. Fresh frozen sections
(20 mm in thickness) were prepared, mounted on gelatin-coated
slides and fixed for 20 min in 220uC methanol. Anti-acetylated
histone H3 antibodies (5 mg/ml in Tris-buffered saline containing
0.25% TX-100 and 5% normal goat serum) were incubated at
room temperature for 3 hr followed by detection with an anti-
rabbit antibody conjugated to Alexa488. Immunofluorescence was
visualized using a UV microscope (Axiophot, Zeiss) and the
appropriate filter sets. D) Representative images of acetylated H3
immunostaining within the hippocampi of a sham, and a 24 hr
injured animal. E) High magnification images of the areas
indicated in (D). Data are presented as mean 6 SEM.
Found at: doi:10.1371/journal.pone.0011383.s002 (9.30 MB TIF)
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